OncoMatch/Clinical Trials/NCT07249905
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Is NCT07249905 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies MDX2003 for lymphoma.
Treatment: MDX2003 — This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 positivity (positive)
Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.
Required: CD20 positivity (positive)
Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07249905 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD19?
Yes, CD19 positivity is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 positivity is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify